BR122020005056A8 - Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2-benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1’r,2’s,3’r,4’s)-2,3-biciclo[2,2,1]heptanodicarboxiimida (lurasidona) - Google Patents

Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2-benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1’r,2’s,3’r,4’s)-2,3-biciclo[2,2,1]heptanodicarboxiimida (lurasidona)

Info

Publication number
BR122020005056A8
BR122020005056A8 BR122020005056A BR122020005056A BR122020005056A8 BR 122020005056 A8 BR122020005056 A8 BR 122020005056A8 BR 122020005056 A BR122020005056 A BR 122020005056A BR 122020005056 A BR122020005056 A BR 122020005056A BR 122020005056 A8 BR122020005056 A8 BR 122020005056A8
Authority
BR
Brazil
Prior art keywords
lurasidone
tetramethylene
piperazinyl
butyl
heptanodicarboxiimide
Prior art date
Application number
BR122020005056A
Other languages
English (en)
Other versions
BR122020005056A2 (pt
BR122020005056B1 (pt
Inventor
Fujihara Kazuyuki
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122020005056(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of BR122020005056A2 publication Critical patent/BR122020005056A2/pt
Publication of BR122020005056A8 publication Critical patent/BR122020005056A8/pt
Publication of BR122020005056B1 publication Critical patent/BR122020005056B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A presente invenção refere-se a uma preparação para administração oral incluindo: um amido pré-gelatinizado contendo cloridrato de N-[4-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-(2R,3R)-2,3-tetrametileno-butil]-(1?R,2?S,3?R,4?S)-2,3-biciclo[2,2,1]heptanodicarboxiimida (lurasidona) representado pela fórmula (1) como ingrediente ativo; um excipiente solúvel em água; e um ligante polimérico solúvel em água, a preparação apresentando um nível invariante de comportamento em eluição mesmo quando o teor de seu ingrediente ativo é variado.
BR122020005056-0A 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona) BR122020005056B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-153508 2005-05-26
JP2005153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja) 2005-05-26 2006-05-26 医薬品組成物

Publications (3)

Publication Number Publication Date
BR122020005056A2 BR122020005056A2 (pt) 2010-11-23
BR122020005056A8 true BR122020005056A8 (pt) 2022-11-22
BR122020005056B1 BR122020005056B1 (pt) 2023-01-10

Family

ID=37452103

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0611409A BRPI0611409B8 (pt) 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona
BR122020005056-0A BR122020005056B1 (pt) 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0611409A BRPI0611409B8 (pt) 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona

Country Status (22)

Country Link
US (5) US8729085B2 (pt)
EP (2) EP1884242B1 (pt)
JP (2) JP4733120B2 (pt)
KR (2) KR101380088B1 (pt)
CN (2) CN101184489B (pt)
AU (1) AU2006250340C1 (pt)
BR (2) BRPI0611409B8 (pt)
CA (1) CA2606510C (pt)
CY (2) CY1114118T1 (pt)
DK (2) DK2422783T3 (pt)
ES (2) ES2408687T3 (pt)
FR (1) FR14C0069I2 (pt)
HK (1) HK1108379A1 (pt)
HU (1) HUS1400051I1 (pt)
LU (1) LU92550I2 (pt)
MX (1) MX2007014872A (pt)
NL (1) NL300690I2 (pt)
PL (1) PL1884242T3 (pt)
PT (1) PT1884242E (pt)
RU (1) RU2398586C3 (pt)
SI (1) SI1884242T1 (pt)
WO (1) WO2006126681A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123678A1 (ja) 2005-05-18 2006-11-23 Dainippon Sumitomo Pharma Co., Ltd. ドロキシドパを含有する安定な錠剤
US8729085B2 (en) * 2005-05-26 2014-05-20 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
US8673353B2 (en) * 2008-02-11 2014-03-18 Dainippon Sumitomo Pharma Co., Ltd Tablet having improved elution properties
AU2009258560B2 (en) 2008-06-13 2014-07-10 Sumitomo Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
CN102170912A (zh) * 2008-09-30 2011-08-31 大洋药品工业株式会社 压缩成型制剂及其制造方法
DK2391355T3 (en) 2009-05-19 2017-02-27 Celgene Corp FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
WO2013014665A1 (en) 2011-07-28 2013-01-31 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EP3318279A1 (en) * 2016-11-02 2018-05-09 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja) 2018-02-28 2019-09-06 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
US20210177197A1 (en) 2018-04-10 2021-06-17 Z-Catering Mitte Gmbh Device for heating food preserved in packaging units and for group catering
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
CN115843243A (zh) * 2020-08-26 2023-03-24 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
KR20230124655A (ko) * 2020-12-23 2023-08-25 스미토모 파마 가부시키가이샤 경구 고형 제제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
NZ302926A (en) 1995-02-28 1998-10-28 Hoechst Marion Roussel Inc Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
NZ503796A (en) 1997-10-20 2001-11-30 Dainippon Pharmaceutical Co Fast-dissolving pharmaceutical composition comprising micronised (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201)
JP4063386B2 (ja) 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
KR100660594B1 (ko) * 1999-03-31 2006-12-22 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
ATE431136T1 (de) * 2000-09-22 2009-05-15 Dainippon Sumitomo Pharma Co Orale zubereitungen mit vorteilhaften zerfallseigenschaften
DK1371646T3 (da) 2001-03-19 2010-07-05 Dainippon Sumitomo Pharma Co Arylsubstitueret alicyklisk forbindelse og medicinsk præparat omfattende det samme
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
ATE431147T1 (de) * 2002-08-22 2009-05-15 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2005000296A1 (en) 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
EP1695699A4 (en) 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US8729085B2 (en) 2005-05-26 2014-05-20 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
BRPI0611409A8 (pt) 2015-12-15
KR101380088B1 (ko) 2014-04-10
MX2007014872A (es) 2008-02-15
US8729085B2 (en) 2014-05-20
BRPI0611409A2 (pt) 2010-11-23
PT1884242E (pt) 2013-05-21
BRPI0611409B8 (pt) 2021-05-25
EP2422783A1 (en) 2012-02-29
ES2535478T3 (es) 2015-05-12
US20090143404A1 (en) 2009-06-04
US9907794B2 (en) 2018-03-06
DK1884242T3 (da) 2013-05-06
HK1108379A1 (en) 2008-05-09
US20140235651A1 (en) 2014-08-21
EP1884242A4 (en) 2009-07-01
CY1114118T1 (el) 2016-06-22
CN102048734B (zh) 2013-11-20
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
CN101184489B (zh) 2011-01-19
KR101552033B1 (ko) 2015-09-09
KR20130122019A (ko) 2013-11-06
RU2007148997A (ru) 2009-07-10
AU2006250340B2 (en) 2012-02-09
RU2398586C2 (ru) 2010-09-10
KR20080012306A (ko) 2008-02-11
FR14C0069I2 (fr) 2015-11-20
RU2398586C3 (ru) 2017-10-04
JPWO2006126681A1 (ja) 2008-12-25
CN102048734A (zh) 2011-05-11
US9555027B2 (en) 2017-01-31
EP1884242B1 (en) 2013-04-17
DK2422783T3 (en) 2015-05-11
AU2006250340A1 (en) 2006-11-30
WO2006126681A1 (ja) 2006-11-30
CA2606510C (en) 2014-07-22
ES2408687T3 (es) 2013-06-21
NL300690I2 (nl) 2017-11-02
BR122020005056A2 (pt) 2010-11-23
PL1884242T3 (pl) 2013-09-30
FR14C0069I1 (fr) 2014-10-24
US20150265611A1 (en) 2015-09-24
LU92550I2 (fr) 2015-11-02
SI1884242T1 (sl) 2013-07-31
EP1884242A1 (en) 2008-02-06
JP4733120B2 (ja) 2011-07-27
JP5285105B2 (ja) 2013-09-11
AU2006250340C1 (en) 2014-06-12
HUS1400051I1 (hu) 2016-10-28
US20180161322A1 (en) 2018-06-14
JP2011126915A (ja) 2011-06-30
BRPI0611409B1 (pt) 2020-12-29
CN101184489A (zh) 2008-05-21
EP2422783B1 (en) 2015-04-08
US20150056284A1 (en) 2015-02-26
BR122020005056B1 (pt) 2023-01-10
US8883794B2 (en) 2014-11-11
CA2606510A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
BR122020005056A8 (pt) Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2-benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1’r,2’s,3’r,4’s)-2,3-biciclo[2,2,1]heptanodicarboxiimida (lurasidona)
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2458920C2 (ru) Новые соединения
BR0214344A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
DE602005012306D1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
NO20084874L (no) Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
ATE528005T1 (de) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
BRPI0407097A (pt) Antagonista do casr
ATE472542T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
BRPI0511874A (pt) derivados da pirrolopiridina
MA31432B1 (fr) Metabolites de derives de (thio) carbamoyl-cyclohexane
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.